Evidence map›Paper›PMID 31047960›Full record

ArticleJournal of pain and symptom management2019

Deleterious Effects of Higher Body Mass Index on Subjective and Objective Measures of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors.

Iva Petrovchich, Kord M Kober, Laura Wagner, Steven M Paul, Gary Abrams, Margaret A Chesney, Kimberly Topp, Betty Smoot, Mark Schumacher, Yvette P Conley and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pain and symptom management, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Chemotherapy-Induced Peripheral Neuropathy.Handbook of experimental pharmacology · 2023
    Article
  7. Article
  8. Review
  9. Neuroendocrine Stress Axis-Dependence of Duloxetine Analgesia (Anti-Hyperalgesia) in Chemotherapy-Induced Peripheral Neuropathy.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022
    Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Iva PetrovchichSchool of Nursing, University of California, San Francisco, California, USA.
Kord M KoberSchool of Nursing, University of California, San Francisco, California, USA.
Laura WagnerSchool of Nursing, University of California, San Francisco, California, USA.
Steven M PaulSchool of Nursing, University of California, San Francisco, California, USA.
Gary AbramsSchool of Medicine, University of California, San Francisco, California, USA.
Margaret A ChesneySchool of Medicine, University of California, San Francisco, California, USA.
Kimberly ToppSchool of Medicine, University of California, San Francisco, California, USA.
Betty SmootSchool of Medicine, University of California, San Francisco, California, USA.
Mark SchumacherSchool of Medicine, University of California, San Francisco, California, USA.
Yvette P ConleySchool of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Marilyn HammerMount Sinai Medical Center, New York, New York, USA.
Jon D LevineSchool of Medicine, University of California, San Francisco, California, USA.
Christine MiaskowskiSchool of Nursing, University of California, San Francisco, California, USA. Electronic address: chris.miaskowski@ucsf.edu.
University of California, San Francisco · USMount Sinai Medical Center · USUniversity of Pittsburgh · US

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Characterization of and Treatment for Chemotherapy NeuropathyR01CA151692 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MIASKOWSKI, CHRISTINE A. · 2011 to 2015
$6.4M
Advancing the Science of Symptom Management in Oncology PatientsK05CA168960 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MIASKOWSKI, CHRISTINE A. · 2013 to 2017
$453k
NCATS NIH HHS UL1 TR000004NCI NIH HHS K05 CA168960NCI NIH HHS R01 CA151692
6 · The paper itself

Abstract

contextRecent, albeit, limited evidence suggests that body mass index (BMI) may be a modifiable risk factor to reduce the deleterious effects of chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors.

objectivesTo evaluate for differences in demographic, clinical, pain, sensation, and balance characteristics among three BMI groups. We hypothesized that as BMI increased, survivors would report higher pain intensity scores and have significant decrements in measures of sensation and balance.

methodsA total of 416 survivors with CIPN were evaluated using subjective and objective measures of CIPN. Survivors were divided into three BMI groups (i.e., normal weight, overweight, and obese). Differences among the BMI groups were evaluated using parametric and nonparametric statistics.

resultsOf the 416 survivors, 45.4% were normal weight, 32.5% were overweight, and 22.1% were obese. Compared with the normal-weight group, survivors in the other two groups had lower functional status scores, a higher comorbidity burden, higher pain intensity scores, and higher interference scores. In addition, compared with the normal-weight group, survivors in the other two BMI groups had significantly worse balance scores.

conclusionOur findings support the hypothesis that as BMI increased, pain sensation and balance characteristics worsened. Our findings suggest that nutritional counseling as well as exercise and weight management programs in survivors with CIPN may improve these clinically important problems.

Indexed as

Body Mass IndexCancer SurvivorsAgedAntineoplastic AgentsFemaleHumansMaleMiddle AgedNeoplasmsPeripheral Nervous System DiseasesQuality of LifeRisk FactorsAntineoplastic Agentsbalancebody mass indexcancer survivorChemotherapyperipheral neuropathyplatinumtaxane

Identifiers

PMID31047960
PMCPMC6679783
OpenAlexW2942849113

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.